"目录号: HY-14291
Metabolic Enzyme/Protease-
Vildagliptin (LAF-237; NVP-LAF 237)能抑制DPP-4，IC50为2.3 nM。
Dipeptidyl Peptidase
相关产品
Sitagliptin-Talabostat mesylate-Saxagliptin-Linagliptin-Teneligliptin-Omarigliptin-Anagliptin-Trelagliptin-Alogliptin Benzoate-DBPR108-UAMC00039 dihydrochloride-Dutogliptin-Gosogliptin-Prodipine hydrochloride-
生物活性
Description
Vildagliptin (LAF-237; NVP-LAF 237) inhibits DPP-4 with IC50 of 2.3 nM.IC50 Value: 2.3 nM[1]Target: DPP-4in vitro: Vildagliptin is an N-substituted glycyl-2-cyanopyrrolidine (figure 2). It is a potent competitive and reversible inhibitor of human and rodent DPP-4 in vitro, with a median inhibitory concentration (IC50) ~2-3 nmol/L. Importantly, vildagliptin inhibits DPP-4 with high specificity relative to other similar peptidases where its IC50 exceeds 200 mol/L [1].in vivo: Compared to age-, gender-, BMI-matched subjects with normal renal function, the mean AUC of vildagliptin after 14 days in patients with mild, moderate, and severe RI increased by 40%, 71%, and 100%, respectively [2]. The treatment was effective in modulating stress in pancreatic tissue, both by reducing levels of stress markers as well as by increasing activity of SOD and catalase. After analyzing the pancreatic histology, we found that vildagliptin was also able to preserve islets and pancreatic β-cells, especially at the concentration of 5 mg/kg [3].Clinical trial: FDA approved drug.
Clinical Trial
NCT01766778
Novartis Pharmaceuticals-Novartis
Type-2 Diabetes Mellitus
May 13, 2013
Phase 4
NCT00952991
Mayo Clinic-Novartis Pharmaceuticals
Diabetes Mellitus, Non-Insulin-Dependent
May 2005
Phase 3
NCT00419887
Novartis
Healthy
September 2006
Phase 1
NCT00414947
Novartis
Healthy
December 2006
Phase 1
NCT02002221
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus (T2DM)
December 2013
Phase 4
NCT00099944
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
May 2004
Phase 3
NCT01309698
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes
February 2011
Phase 4
NCT01649466
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
August 2012
Phase 4
NCT01882907
Pusan National University Hospital
Type 2 Diabetes
December 2009
Phase 4
NCT01686932
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus Type 2
November 2012
Phase 4
NCT01582243
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
April 2013
Phase 4
NCT01541956
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes
February 2012
Phase 4
NCT01147276
Lund University
Diabetes-Hypoglycemia
September 2010
Phase 4
NCT00980356
Medical University of Vienna
Diabetes Mellitus
September 2009
Phase 2
NCT01827280
Rio de Janeiro State University-Laboratory for Clinical and Experimental Research on Vascular Biology
1- Microvascular Function-2-oxidative Stress-3-inflammation
April 2013
Phase 4
NCT01426802
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
October 2010
Phase 4
NCT02145611
Dr. José Fernando Vilela-Martin MD PhD-Novartis-Hospital de Base
Type 2 Diabetes Mellitus-Hypertension-Endothelial Dysfunction
July 2013
Phase 4
NCT01219400
Lund University
Diabetes
January 2012
Phase 4
NCT00936234
Johann Wolfgang Goethe University Hospital
SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
July 2009
Phase 2-Phase 3
NCT00633997
Novartis
Diabetes Mellitus, Type 2
February 2008
Phase 1-Phase 2
NCT01582230
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
April 2012
Phase 3
NCT01257451
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
December 2010
Phase 3
NCT00380445
Novartis
Diabetes Mellitus, Type 2
January 2006
Phase 3
NCT01497522
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
December 2011
Phase 3
NCT00099853
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
May 2004
Phase 3
NCT01398592
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus Type 2
June 2011
Phase 4
NCT01099137
Seoul National University Bundang Hospital
Diabetes
January 2010
Phase 4
NCT01559025
Federal University of São Paulo-Novartis
Type 1 Diabetes-Insulin Dependent Diabetes-Juvenile Onset Diabetes Mellitus-Autoimmune Diabetes
March 2014
Phase 3
NCT00138554
Novartis
Diabetes Mellitus, Type 2
November 2004
Phase 3
NCT00101712
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
October 2004
Phase 3
NCT02475070
Lund University
Type 2 Diabetes
January 2016
Phase 4
NCT00894868
Novartis Pharmaceuticals-Novartis
Congestive Heart Failure-Type II Diabetes Mellitus
May 2009
Phase 4
NCT01528254
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
March 30, 2012
Phase 4
NCT00099866
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
January 2004
Phase 3
NCT00396071
Novartis Pharmaceuticals-Novartis
Diabetes Mellitus, Type 2
October 2006
Phase 3
NCT02816970
Genuine Research Center, Egypt-EVA pharma, Egypt
Healthy
February 2014
Phase 1
NCT00567047
Novartis
Type-2 Diabetes
July 2007
Phase 1
NCT01000688
Radboud University
Type 2 Diabetes-Endothelial Dysfunction
January 2010
Phase 3
NCT00380380
Novartis
Diabetes Mellitus, Type 2
January 2006
Phase 3
NCT01758380
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
January 2013
Phase 4
NCT00616811
Novartis
Diabetes Mellitus, Type 2
January 2008
Phase 3
NCT01233622
Novartis
Type 2 Diabetes Mellitus
October 2010
Phase 3
NCT00765830
Novartis
Diabetes Mellitus, Type 2-Renal Insufficiency
September 2008
Phase 3
NCT01196546
Novartis
Type 2 Diabetes Mellitus
March 2010
Phase 4
NCT00138541
Novartis
Diabetes Mellitus, Type 2
October 2004
Phase 3
NCT01262586
Novartis Pharmaceuticals-Novartis
Type II Diabetes Mellitus
November 2010
Phase 3
NCT00138606
Novartis
Diabetes Mellitus, Type 2
January 2005
Phase 3
NCT01159249
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes
June 2010
Phase 3
NCT01357252
Novartis Pharmaceuticals-Novartis
Type 2 Diabetes Mellitus
April 2011
Phase 3
NCT01822548
Azienda Ospedaliero-Universitaria di Parma
Type 2